Open in interactive viewer → charts, metric popovers & call review

Milestone Cuts 30% of Itself to Keep a $1 Million-a-Quarter Launch Alive

Scripts up 50%, formulary coverage to two-thirds of commercial lives — and the stock is down 51% because the refill rate is 1.3 and revenue per script has barely budged
MIST · Earnings Call · 2026-11-13

The Quarter in One Number

Milestone's third quarter had a genuinely good-looking top line in units and a genuinely bad-looking one in dollars, and management led with the former. Prescriptions of CARDAMYST in PSVT reached roughly 1,800, up 50% sequentially, with about 3,400 written since launch. Unique prescribers climbed 16% to roughly 750, bringing the cumulative base to about 1,600, and formulary coverage — the metric this management team has trained investors to watch — expanded from about 50% of commercially insured lives in August to roughly two-thirds today. Then Anthony Krick read the actual number: “Net product revenue was $1.0 million for the third quarter of 2026, compared with $0.6 million in the second quarter of 2026” — Anthony Krick, Chief Financial Officer · 2026-11-13. Nine-month revenue: $1.8 million. Against a market capitalization of roughly $82 million. Do the arithmetic the company didn't: $1.0 million across ~1,800 scripts is a bit over $550 of net revenue per prescription. Note also that the Q2 base has quietly migrated — last quarter the CEO casually described Q2 as “Q2, I guess, we had 1,500 scripts over 1,300 patients” — Joseph Oliveto, Chief Executive Officer · 2026-08-12, whereas this quarter it is "more than 1,200." Depending on which base you anchor to, net revenue per script either rose ~10% or ~39% while commercial coverage supposedly tripled from 25% to two-thirds over three quarters. The patient counts are consistent (1,300 in Q2, 1,400 in Q3); the script base is not. That ambiguity matters, because the whole bull case rests on coverage pull-through into price. And the word that has vanished from the script is the one that would settle it. Average selling price ranked among this company's top-10 keywords last quarter, when Joe Oliveto promised “it would have the most impacts on revenues, on improved average selling prices because... we'll just have less denial conversion associated with the products” — Joseph Oliveto, Chief Executive Officer · 2026-08-12. This quarter: not a mention. Gross-to-net is now the dog that didn't bark.

What Actually Changed — and It Wasn't the P&L

The new information in this report is organizational, not commercial. Milestone is cutting roughly 30% of operating expense, taking about $2 million in one-time charges, and finishing by Q1 2027. The mechanics: internalizing ~45 contracted sales reps (already trimmed from ~60 in August) as employees, killing low-return marketing programs, shrinking headquarters, and losing both the CFO and the CMO. A VP of Finance is now Principal Financial and Principal Accounting Officer. Ted Tenthoff's sign-off — "wishing Amit and David all the best" — is the tell that this was not a planned succession. This is a company converting itself from a launch organization into a maintenance organization, and it says so plainly: cost efficiency measures are the headline, and the runway claim — operating cash into late 2028, more than a year beyond prior guidance, carrying through the ReVeRA-301 readout in the second half of 2028 — is the deliverable. Two caveats. First, part of that runway is bought with a balance-sheet amendment, not operating discipline: the PIK interest period on the RTW Investments note purchase agreement extends from March 2027 to March 2029. Deferring interest is a real extension of liquidity and a real increase in eventual claims on equity. Second, the balance sheet is already thin in equity terms — liabilities at 90% of assets — while effective net cash has been rebuilt to near the 2019 record. The restructuring is being financed by that rebuilt cash pile, and the pile itself came from capital markets, not from CARDAMYST.

The Channel Management Just Deprioritized Is Its Own Top Keyword

The most interesting tension on the call is structural. The single highest-momentum keyword in Milestone's own third-quarter vocabulary is the emergency department — the setting where PSVT patients actually present, where adenosine has been the only option for three decades, and where Olivia Brayer's channel checks suggest real enthusiasm. Management spent four minutes explaining why it will not pursue it.

In the emergency department... to actually get the product into the system in emergency departments around the country is a big lift. Just to get it into protocols, emergency medicine physicians are very protocol-driven... We'll get there, but it's not our focus or our priority in the next 12 or 18 months.

Lorenz Muller, Chief Commercial Officer · 2026-11-13
That is a defensible call for a 45-rep company. It is also a warning about the size of the outpatient opportunity they are choosing instead. The core problem, per Oliveto, is not demand:

We talked about things like entering a market that hadn't had any new drugs enter it for three decades since adenosine. That was an unknown that we had going into this launch... That seems to be the major issue.

Joseph Oliveto, Chief Executive Officer · 2026-11-13
In other words, the friction points are behavioral inertia and workflow, not clinical need. A rep force cut to 45 is a strange instrument for solving a behavioral-inertia problem. Meanwhile the depth question — 40% of prescribers have written for more than one patient, and the refill rate ran 1.3 scripts per patient in Q3 — is the number that should govern the multiple. Management insists fill rates are fine: “our fill rates are not the primary obstacle toward growing the drug” — Lorenz Muller, Chief Commercial Officer · 2026-11-13.

What Fell Off, and What's Being Sat On

Patient activation, ranked fifth in this company's keywords last quarter and pitched as the second-half catalyst, has been deferred into a future disclosure: “We haven't presented data yet because it's still early” — Lorenz Muller, Chief Commercial Officer · 2026-11-13. The August promise of measurable impact "toward the end of the year" has become measurement deferred to planning season. Medicare is now explicitly de-prioritized in favor of medical necessity exception pathways — “we won't chase broad Part D coverage at any rebate level” — Lorenz Muller, Chief Commercial Officer · 2026-11-13. That is price discipline, and it deserves credit. But it also means roughly half the PSVT population has no scalable access route until regional plans come on in 2027. And retail distribution, once the strategic centerpiece of making the drug easy to get, is now a footnote. Finally, this is not a Milestone-only story. Formulary coverage is the shared theme across this week's small-cap launch reporters — Journey Medical's Emrosi also reported formulary coverage expanding, and ACOG flagged the opposite. The market is currently discriminating hard between launches where reimbursement translates into dollars and launches where it translates into scripts.

The Tape Doesn't Argue

Operating loss deepened to roughly $26 million in the quarter before this one, and the equity has repriced accordingly: MIST is down 51% over thirteen weeks and 57% from its September 3 peak of $1.21. The drawdown began weeks before this print, which means the market was already pricing a script trajectory, not a cost story. What the call offers is time, not growth. A 30% cost cut, a two-year PIK extension, and a Phase III readout in late 2028 mean Milestone can now fund the AFib-RVR option — AFib RVR, powered on a symptomatic-benefit endpoint targeting 45% versus 20% responders — without returning to market. That is a genuine strategic achievement for a company this size. But the near-term equity case is still a PSVT launch generating about $555 per prescription. Until management reinstates the average-selling-price conversation it abandoned this quarter, the two-thirds formulary coverage number is a promise rather than a P&L fact — and a 1.3 refill rate says the market is still trialing the drug, not relying on it.